# Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026 Canonical URL: https://biopharmsignal.com/news/VVOS/vivos-therapeutics-to-participate-in-the-small-cap-showcase-wtr-insights-on-june-ea30ba7e Ticker: VVOS Company: Vivos Therapeutics Source: Vivos Therapeutics Published: 2026-06-08 17:39 EST ## Summary Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026... ## Article Body Vivos Therapeutics, Inc. (“Vivos” or the “Company’’) (NASDAQ: VVOS) , a leading medical device and healthcare services company focused on the treatment of breathing-related sleep disorders and associated chronic health conditions, including obstructive sleep apnea (“OSA”), today announced that members of its executive management team will participate in The Small Cap Showcase & WTR Insights, taking place on June 9, 2026, in New York City. Representing the Company, Kirk Hunstman, CEO, will deliver a corporate presentation at 11:30 am ET and will participate in one-on-one meetings with pre-qualified investors throughout the day. The Small Cap Showcase & WTR Insights brings together executive management teams from approximately 20 micro and small-cap companies across a diverse range of industries. This event provides a unique forum to discover differentiated investment opportunities through company presentations, one-on-one meetings, industry insights, and networking. For more information about The Small Cap Showcase & WTR Insights, please visit www.smallcapshowcase.com . A live webcast of the Company's presentation will be available at: Vivos Conference Webcast A replay of the presentation will be available following the event and may also be accessed through the Company's website under the Investor Relations section. About Vivos Therapeutics, Inc. Vivos Therapeutics, Inc. (NASDAQ: VVOS) is a medical technology and healthcare services company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the U.S. Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate-to-severe OSA in children. OSA affects over 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA. Founded in 2016 and based in Littleton, Colorado, Vivos is working to change this. Through innovative technology, education, and acquisitions of, or commercial collaborations with, sleep healthcare providers, Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly. Vivos calls the use of its appliances and protocols to treat OSA The Vivos Method , which offers a proprietary, clinically effective solution that is nonsurgical, noninvasive, and nonpharmaceutical, providing hope to allow patients to Breathe New Life . For more information, visit www.vivos.com . Cautionary Note Regarding Forward-Looking Statements This press release, the presentations described herein, and statements of the Company’s management and third parties made in connection therewith contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) concerning future events. Words such as “may”, “should”, “expects”, “projects,” “intends”, “plans”, “believes”, “anticipates”, “hopes”, “estimates”, “aim,” “goal” and derivations of such words and similar expressions about the future are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon several assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Vivos’ control. Actual results (including the actual benefits of debt restructuring, potential equity raise, the Company’s new model and actual revenue and cash flow results) may differ materially and adversely from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to: (i) the risk that Vivos may be unable to raise the required new equity timely or in sufficient amounts, which would cause the commitment debt-to-equity exchange to become null and void; (ii) the risk that Vivos may be unable benefit fully or at all from the transactions discussed herein, even if they are consummated, (iii) the risk that Vivos may be unable to implement revenue, sales and marketing strategies and other strategies that increase revenues, (iv) the risk that some patients may not achieve the desired results from using Vivos products, (v) risks associated with regulatory scrutiny of and adverse publicity in the sleep apnea treatment sector; (vi) the risk that Vivos may be unable to secure additional financings on reasonable terms when needed, if at all, or maintain its Nasdaq listing due to, among other things, a deficiency in its stockholders’ equity; (vii) market and other conditions, and (viii) other risk factors described in Vivos’ filings with the SEC. Vivos’ filings can be obtained free of charge at https://vivos.com/investors/sec-filings/. Except to the extent required by law, Vivos expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Vivos’ expectations with respect thereto or any change in events, conditions, or circumstances on which any statement is based. Vivos Investor Relations and Media Contact: Jennifer Hauser Investor Relations Contact investors@vivoslife.com ## Recent Company News - 2026-06-30 12:45 EST — [Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants](https://biopharmsignal.com/news/VVOS/vivos-vida-appliance-shows-statistically-significant-improvement-in-insomnia-sev-76ccf0ec) — Source: Vivos Therapeutics - 2026-06-22 12:30 EST — [Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-and-streeterville-extend-timeframe-of-strategic-financing-agr-76425cab) — Source: Vivos Therapeutics - 2026-06-11 12:30 EST — [Vivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-intent-to-file-a-registration-statement-for-a-propo-e20065b2) — Source: Vivos Therapeutics - 2026-06-10 13:03 EST — [Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-announces-key-collaboration-agreement-with-multi-location-flo-8a573b10) — Source: Vivos Therapeutics - 2026-06-08 17:39 EST — [Vivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026](https://biopharmsignal.com/news/VVOS/vivos-therapeutics-to-participate-in-the-small-cap-showcase-wtr-insights-on-june-ea30ba7e) — Source: Vivos Therapeutics ## Related News - 2026-07-29 20:05 EST — SERA — [SERA PROGNOSTICS ANNOUNCES CONFERENCE CALL AND WEBCAST OF SECOND QUARTER FISCAL YEAR 2026 FINANCIAL RESULTS ON AUGUST 12, 2026](https://biopharmsignal.com/news/SERA/sera-prognostics-announces-conference-call-and-webcast-of-second-quarter-fiscal--2a2c0c5a) - 2026-07-29 20:05 EST — VKTX — [Viking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/VKTX/viking-therapeutics-reports-second-quarter-2026-financial-results-and-provides-c-2f09b8ce) - 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9) - 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627) - 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)